Annexin Pharmaceuticals Investor Relations Material
Annexin Pharmaceuticals AB (publ) is a Swedish biotechnology company that develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, human recombinant protein that protects and repairs blood vessels and counters inflammation. It offers Annexin A5, which is the only drug approved in Canada with this mechanism of action. The company was founded in 2014 and is based in Stockholm, Sweden.
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023